Biotron US Market +56%, page-9

Wrong, this run is built on:

A. A grossly undervalued SP;
B. An announcement from BIT that its well researched drug is well placed to combat the latest outbreak of the Coronavirus;
C. An upcoming conference to present the data from last years' 2nd stage clinical trial; and
D. The fact that BIT is a first-in-class major virus biotech co., well positioned for a major pharma deal.

Don't listen to this recent influx of down-rampers, do your research - there are plenty of quality contributors to this forum.
The sell of is due to day-traders and bots, volume like this is irresistible to them.

There's too much in the works for BIT atm, sell and you miss the boat.

All IMO.